542900login-checkCareDx Demonstrates Global Leadership at 29th International Congress of The Transplantation Society |
Over 25 Abstracts Highlight Value of AlloSure and AlloSeq cfDNA
BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its leading participation in the 29th International Congress of The Transplantation Society (TTS 2022) taking place September 10-14 in Buenos Aires, Argentina.
Transplant physicians will present data from over 25 abstracts demonstrating the value of AlloSure® donor-derived cell-free DNA (dd-cfDNA) and AlloSeq cfDNA in clinical practice, and emerging trends and innovation in transplantation, including artificial intelligence and the potential use of CareDx’s molecular testing services for xenotransplantation surveillance. Read the complete press release on CareDx.com.
542900login-checkCareDx Demonstrates Global Leadership at 29th International Congress of The Transplantation Society |